A new era of quantitative biology enabled by mass spectrometry based proteomic technologies has arrived. We can now define the content, relative abundance, modification states and interaction partners of proteins in a dynamic and temporal manner on a near-global basis in organelles, whole cells and clinical samples, providing information of unprecedented detail. At the Broad Institute we are developing and applying these technologies in a wide array of studies including defining the subcellular locations of proteins in health and disease, connecting cancer genotype to molecular phenotype, unraveling the basis of the innate-immune response, identifying the mechanism of action of drug-like molecules and to discover and verify protein biomarkers of disease. I will present the results of several recent studies that convey a sense of the breadth and depth of application of modern quantitative proteomics to biology and medicine.
Biography of Steve Carr
Dr. Carr is Director of Proteomics at the Broad Institute of MIT and Harvard. He is internationally recognized as a leader in the development of novel proteomics methods and in their application in biology and medicine. Steve and his group collaborate with scientists throughout the Broad Institute community (comprised of MIT, Harvard University Faculty of Arts and Sciences, Harvard Medical School, and the 17 Harvard-affiliated hospitals) to apply state-of-the-art proteomics technology to address compelling questions in biology, chemistry, and clinical medicine. Research in his laboratory focuses on developing and applying new technologies to quantify proteins and their modifications and interaction partners in tissues, cells and biofluids with high sensitivity and specificity; improving informatics for peptide and protein assignment using mass spectrometry (MS) data and integration of MS-derived data with genomic data to understand disease biology and drug effects. The group also has a major focus on the discovery and quantitative verification of biomarkers for major diseases including cancer, cardiovascular and infectious diseases as well as pharmacodynamics markers of drug response. Steve has over 300 publications on the development and use of proteomics and biological mass spectrometry, and he is Deputy Editor of the journal Molecular and Cellular Proteomics, the leading journal in the field of Proteomics.